AU768299B2 - Formulation for spray-drying large porous particles - Google Patents

Formulation for spray-drying large porous particles Download PDF

Info

Publication number
AU768299B2
AU768299B2 AU70666/00A AU7066600A AU768299B2 AU 768299 B2 AU768299 B2 AU 768299B2 AU 70666/00 A AU70666/00 A AU 70666/00A AU 7066600 A AU7066600 A AU 7066600A AU 768299 B2 AU768299 B2 AU 768299B2
Authority
AU
Australia
Prior art keywords
particles
salt
phospholipid
microns
multivalent salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU70666/00A
Other languages
English (en)
Other versions
AU7066600A (en
Inventor
Richard P. Batycky
Giovanni Caponetti
Michael M. Lipp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alkermes Inc
Original Assignee
Advanced Inhalation Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Inhalation Research Inc filed Critical Advanced Inhalation Research Inc
Publication of AU7066600A publication Critical patent/AU7066600A/en
Application granted granted Critical
Publication of AU768299B2 publication Critical patent/AU768299B2/en
Assigned to ALKERMES, INC. reassignment ALKERMES, INC. Alteration of Name(s) in Register under S187 Assignors: ADVANCED INHALATION RESEARCH, INC.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU70666/00A 1999-08-25 2000-08-23 Formulation for spray-drying large porous particles Ceased AU768299B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15066299P 1999-08-25 1999-08-25
US60/150662 1999-08-25
PCT/US2000/023118 WO2001013892A2 (en) 1999-08-25 2000-08-23 Large porous particles by spray-drying

Publications (2)

Publication Number Publication Date
AU7066600A AU7066600A (en) 2001-03-19
AU768299B2 true AU768299B2 (en) 2003-12-04

Family

ID=22535487

Family Applications (1)

Application Number Title Priority Date Filing Date
AU70666/00A Ceased AU768299B2 (en) 1999-08-25 2000-08-23 Formulation for spray-drying large porous particles

Country Status (7)

Country Link
EP (1) EP1210069B1 (https=)
JP (1) JP2003507411A (https=)
AT (1) ATE285755T1 (https=)
AU (1) AU768299B2 (https=)
CA (1) CA2383491A1 (https=)
DE (1) DE60017152D1 (https=)
WO (1) WO2001013892A2 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US7871598B1 (en) * 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
ES2525087T5 (es) 2000-05-10 2018-06-28 Novartis Ag Polvos basados en fosfolípidos para administración de fármacos
US6848197B2 (en) * 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
EP1390012A4 (en) * 2001-04-26 2009-10-28 Novartis Ag NEW METHODS AND COMPOSITIONS FOR RELEASING MACROMOLECULES TO OR BY THE AIRWAY
GB0120123D0 (en) * 2001-08-17 2001-10-10 Upperton Ltd Preparation of microparticles
EP1458361A4 (en) * 2001-11-20 2007-04-25 Advanced Inhalation Res Inc COMPOSITIONS FOR DISTRIBUTING PRODUCTS WITH LASTING EFFECT
JP2005514393A (ja) 2001-12-19 2005-05-19 ネクター セラピューティクス アミノグリコシドの肺への供給
AU2003287132B2 (en) * 2002-12-13 2009-03-12 Adagit Pharmaceutical porous particles
CA2754691C (en) * 2009-03-26 2019-07-30 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
US20120058198A1 (en) * 2009-03-26 2012-03-08 Pulmatrix, Inc. Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis
AU2011296343B2 (en) * 2010-08-30 2015-12-10 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
EP2464346A1 (en) 2010-08-30 2012-06-20 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
EP3470057B1 (en) 2010-09-29 2021-11-03 Pulmatrix Operating Company, Inc. Cationic dry powders comprising magnesium salt
RU2017144619A (ru) 2010-09-29 2019-02-20 Пулмэтрикс, Инк. Катионы одновалентных металлов сухих порошков для ингаляций
CN107596518B (zh) 2012-02-29 2021-04-23 普马特里克斯营业公司 可吸入干粉剂
JP6473738B2 (ja) 2013-04-01 2019-02-20 パルマトリックス，インコーポレイテッド チオトロピウム乾燥粉末
WO2015120389A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders
PL3104854T3 (pl) 2014-02-10 2020-11-30 Respivant Sciences Gmbh Stabilizatory komórek tucznych do leczenia choroby płuc
WO2016067252A1 (en) 2014-10-31 2016-05-06 Glaxosmithkline Intellectual Property Development Limited Powder formulation
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
WO2017027387A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
EP3506893A4 (en) 2016-08-31 2020-01-22 Respivant Sciences GmbH CROMOLYN COMPOSITIONS FOR THE TREATMENT OF CHRONIC COUGH DUE TO IDIOPATHIC PULMONAL FIBROSIS
JP2019531308A (ja) 2016-10-07 2019-10-31 レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングＲｅｓｐｉｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ 肺線維症の治療のためのクロモリン組成物
CA3133804A1 (en) * 2019-03-22 2020-10-01 Mannkind Corporation Inhalable dry powders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996032149A1 (en) * 1995-04-14 1996-10-17 Inhale Therapeutic Systems Pulmonary delivery of aerosolized medicaments
WO1997026863A1 (de) * 1996-01-24 1997-07-31 Byk Gulden Lomberg Chemische Fabrik Gmbh Verfahren zur herstellung von pulverförmigen lungensurfactant-zubereitungen
WO1998031346A1 (en) * 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996032149A1 (en) * 1995-04-14 1996-10-17 Inhale Therapeutic Systems Pulmonary delivery of aerosolized medicaments
WO1997026863A1 (de) * 1996-01-24 1997-07-31 Byk Gulden Lomberg Chemische Fabrik Gmbh Verfahren zur herstellung von pulverförmigen lungensurfactant-zubereitungen
WO1998031346A1 (en) * 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation

Also Published As

Publication number Publication date
ATE285755T1 (de) 2005-01-15
DE60017152D1 (de) 2005-02-03
CA2383491A1 (en) 2001-03-01
WO2001013892A2 (en) 2001-03-01
EP1210069A2 (en) 2002-06-05
JP2003507411A (ja) 2003-02-25
WO2001013892A3 (en) 2001-06-21
AU7066600A (en) 2001-03-19
EP1210069B1 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
US7807200B2 (en) Formulations for spray-drying large porous particles
AU764738B2 (en) Use of simple amino acids to form porous particles
AU768299B2 (en) Formulation for spray-drying large porous particles
CA2341624C (en) Stable spray-dried protein formulations
US6956021B1 (en) Stable spray-dried protein formulations
US7252840B1 (en) Use of simple amino acids to form porous particles
US20040018243A1 (en) Modulation of release from dry powder formulations
EP1370246A2 (en) Modulation of release from dry powder formulations
AU2002242253A1 (en) Modulation of release from dry powder formulations
HK1101138A (en) Stable spray-dried protein formulations
EP1767195A2 (en) Stable spray-dried protein formulations

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)